This HTML5 document contains 96 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00869/identifier/chebi/
n7http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/drugbank/dosage/
n28http://linked.opendata.cz/resource/drugbank/mixture/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00869/identifier/wikipedia/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00869/identifier/pharmgkb/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00869/identifier/kegg-compound/
n23http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB00869/identifier/bindingdb/
admshttp://www.w3.org/ns/adms#
n25http://www.rxlist.com/cgi/generic/
n18http://linked.opendata.cz/resource/drugbank/patent/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00869/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00869/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n4http://www.drugs.com/cdi/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00869/identifier/national-drug-code-directory/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n26http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00869
rdf:type
n5:Drug
n5:description
Dorzolamide is a carbonic anhydrase (CA) inhibitor. It is used in ophthalmic solutions (Trusopt) to lower intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension.
n5:dosage
n24:271B5313-363D-11E5-9242-09173F13E4C5 n24:271B5311-363D-11E5-9242-09173F13E4C5 n24:271B5312-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Plummer CE, MacKay EO, Gelatt KN: Comparison of the effects of topical administration of a fixed combination of dorzolamide-timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs. Vet Ophthalmol. 2006 Jul-Aug;9(4):245-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16771760 # Grover S, Apushkin MA, Fishman GA: Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 2006 May;141(5):850-8. Epub 2006 Mar 20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16546110 # Almeida GC Jr, Faria e Souza SJ: Effect of topical dorzolamide on rabbit central corneal thickness. Braz J Med Biol Res. 2006 Feb;39(2):277-81. Epub 2006 Feb 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16470316 # Martens-Lobenhoffer J, Banditt P: Clinical pharmacokinetics of dorzolamide. Clin Pharmacokinet. 2002;41(3):197-205. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11929320 # Balfour JA, Wilde MI: Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging. 1997 May;10(5):384-403. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9143858 # Ponticello GS, Sugrue MF, Plazonnet B, Durand-Cavagna G: Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. Pharm Biotechnol. 1998;11:555-74. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9760696
n5:group
approved
n5:halfLife
4 months
n5:indication
For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Also used prophylatically for the inhibition of perioperative IOP increase (before neodynium yttrium aluminum garnet laser posterior capsulotomy).
n5:manufacturer
n7:271B5309-363D-11E5-9242-09173F13E4C5 n7:271B530A-363D-11E5-9242-09173F13E4C5 n7:271B5307-363D-11E5-9242-09173F13E4C5 n7:271B5308-363D-11E5-9242-09173F13E4C5 n7:271B5305-363D-11E5-9242-09173F13E4C5 n7:271B5306-363D-11E5-9242-09173F13E4C5 n7:271B5303-363D-11E5-9242-09173F13E4C5 n7:271B5304-363D-11E5-9242-09173F13E4C5
owl:sameAs
n23:DB00869 n27:DB00869
dcterms:title
Dorzolamide
adms:identifier
n9:C06969 n10:4702 n11:DB00869 n12:D07871 n13:0093-7618-33 n14:PA164748765 n15:50043906 n16:Dorzolamide
n5:mechanismOfAction
Dorzolamide is a sulfonamide and a highly specific carbonic anhydrase II (CA-II) inhibitor, which is the main CA isoenzyme involved in aqueous humor secretion. Inhibition of CA-II in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Dorzolamide also accumulates in red blood cells as a result of CA-II binding, as CA-II is found predominantly in erythrocytes. However, sufficient CA-II activity remains so that adverse effects due to systemic CA inhibition are not observed.
n5:packager
n7:271B52FD-363D-11E5-9242-09173F13E4C5 n7:271B52FE-363D-11E5-9242-09173F13E4C5 n7:271B52FB-363D-11E5-9242-09173F13E4C5 n7:271B52FC-363D-11E5-9242-09173F13E4C5 n7:271B52F9-363D-11E5-9242-09173F13E4C5 n7:271B52FA-363D-11E5-9242-09173F13E4C5 n7:271B5301-363D-11E5-9242-09173F13E4C5 n7:271B5302-363D-11E5-9242-09173F13E4C5 n7:271B52FF-363D-11E5-9242-09173F13E4C5 n7:271B5300-363D-11E5-9242-09173F13E4C5
n5:patent
n18:1329211
n5:routeOfElimination
Dorzolamide is primarily excreted unchanged in the urine; the metabolite also is excreted in urine.
n5:synonym
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide Dorzolamide (4S-trans)-4-(ETHYLAMINO)-5,6-dihydro-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide (4S,trans)-4-(Ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide (4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide Dorzolamida Dorzolamidum 4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide 4S,6S-Dorzolamide Dorzolamid
n5:toxicity
Dizziness, headache, shortness of breath, slow heartbeat, severe asthma, cardiac arrest
n19:hasAHFSCode
n20:52-10-00
n5:mixture
n28:271B52F8-363D-11E5-9242-09173F13E4C5
n5:proteinBinding
~33%
n5:salt
n5:synthesisReference
Laszlo Kovacs, Csaba Szabo, Erika Molnarne, Adrienne Kovacsne-Mezei, Claude Singer, Judith Aronhime, "Method of making dorzolamide hydrochloride." U.S. Patent US20060155132, issued July 13, 2006.
foaf:page
n4:dorzolamide-drops.html n25:dorzolamide.htm
n5:IUPAC-Name
n6:271B5318-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B531E-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B531D-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B531A-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B531B-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B531C-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5316-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B532F-363D-11E5-9242-09173F13E4C5 n6:271B5317-363D-11E5-9242-09173F13E4C5 n6:271B5314-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5315-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n26:S01EC03
n5:H-Bond-Acceptor-Count
n6:271B5324-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5325-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B531F-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5320-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5322-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5321-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5323-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
120279-96-1
n5:containedIn
n17:271B530F-363D-11E5-9242-09173F13E4C5 n17:271B5310-363D-11E5-9242-09173F13E4C5 n17:271B530D-363D-11E5-9242-09173F13E4C5 n17:271B530E-363D-11E5-9242-09173F13E4C5 n17:271B530B-363D-11E5-9242-09173F13E4C5 n17:271B530C-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B532A-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B532C-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B532D-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B532E-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5329-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5328-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B532B-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5319-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5326-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5327-363D-11E5-9242-09173F13E4C5